These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20950056)

  • 1. 5-HT₃ antagonists under development.
    Chong Y; Choo H
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1309-19. PubMed ID: 20950056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.
    Asagarasu A; Matsui T; Hayashi H; Tamaoki S; Yamauchi Y; Minato K; Sato M
    J Med Chem; 2010 Nov; 53(21):7549-63. PubMed ID: 20931963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 5-HT₃ receptor antagonists on peripheral and central diseases.
    Fakhfouri G; Rahimian R; Ghia JE; Khan WI; Dehpour AR
    Drug Discov Today; 2012 Jul; 17(13-14):741-7. PubMed ID: 22390946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Negative Allosteric Modulators of 5-HT₃ Receptors.
    Al Kury LT; Mahgoub M; Howarth FC; Oz M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30513973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders.
    Walstab J; Wohlfarth C; Hovius R; Schmitteckert S; Röth R; Lasitschka F; Wink M; Bönisch H; Niesler B
    Neurogastroenterol Motil; 2014 Jun; 26(6):810-20. PubMed ID: 24708203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT(3) receptors: role in disease and target of drugs.
    Walstab J; Rappold G; Niesler B
    Pharmacol Ther; 2010 Oct; 128(1):146-69. PubMed ID: 20621123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in 5-HT3 receptor pharmacology.
    Thompson AJ
    Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.
    Kris MG; Urba SG; Schwartzberg LS
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):suppl 1-15. PubMed ID: 21370520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
    Spiller R
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():25-31. PubMed ID: 17620085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists.
    Yang Z; Fairfax DJ; Maeng JH; Masih L; Usyatinsky A; Hassler C; Isaacson S; Fitzpatrick K; DeOrazio RJ; Chen J; Harding JP; Isherwood M; Dobritsa S; Christensen KL; Wierschke JD; Bliss BI; Peterson LH; Beer CM; Cioffi C; Lynch M; Rennells WM; Richards JJ; Rust T; Khmelnitsky YL; Cohen ML; Manning DD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6538-41. PubMed ID: 20889341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
    Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
    Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and GI clinical disorders.
    Spiller R
    Neuropharmacology; 2008 Nov; 55(6):1072-80. PubMed ID: 18687345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.